When a peptide company cold-emailed investigative journalist Scott Carney offering a $500 product kit in exchange for a review, they almost certainly expected a glowing endorsement. What they got instead was a mass spectrometry analysis at the University of Colorado Boulder.
The company, Iron Peptides, pitched itself as a “100% made in the USA” supplier of research-grade compounds stepping into the void left by Peptide Sciences, which had been shut down by the FDA.
During onboarding calls, their representative Abe Montran admitted the “made in USA” claim referred only to viling and labeling, with the compounds themselves sourced from Eastern Europe. The company’s address listed Kansas City, but its staff was scattered across Mexico, Uruguay, and California.
Carney sent the samples to Chris Ebmeier, Director of Proteomics and Mass Spectrometry at CU Boulder, who had been involved in early GLP-1 development in the 1990s. Ebmeier ran the vials through an Orbitrap mass spectrometer, one of the most precise instruments available for identifying molecular composition, and compared the results against standardized reference samples.
The findings were unexpected. “As far as I can tell, yes,” Ebmeier confirmed when asked whether the contents matched the labels. He noted the purity came in around 98%, slightly above the advertised 97%, and expressed surprise that an operation at this scale could achieve that consistency.
“A little surprised that it is what it is,” he said. “That there are operations that can make such a large scale of these things at this kind of purity.”
One issue did surface: the BAC water included in the kit lacked the saline content needed for safe injection. Ebmeier noted it “would suck all the water out of your cells.” The QR codes on the bottles, which were supposed to link to certificates of authenticity, led to a generic web page with no useful information.
The clean lab result does not resolve the concerns around these peptides. BPC-157 and TB-500, two of the most widely promoted peptides, have no FDA approval for human use. A review article cited in the video noted that BPC-157 “should be considered investigational and its use approached with caution” given the minimal human data available.
The same pattern applies across most of the peptide market: small clinical trials, mostly rodent studies, and aggressive marketing claims built on top of them.
Ebmeier, when asked directly whether he would inject these himself, was unambiguous. “No. I would not.”
The gray market itself is estimated conservatively at around $100 million, likely an undercount given that product moves internationally without standard reporting. The regulatory picture shifted further when the current administration moved to reclassify peptides away from the stricter oversight applied under the previous FDA framework.
What the Iron Peptides test ultimately demonstrated is that a supplier can lie about its location, misrepresent its supply chain, post non-functional authenticity codes, and still deliver a product that is chemically what it claims to be. As Carney put it, the supplier “was putting more effort into quality control than Iron Peptides was into their overall credibility.”
That is not an endorsement of the product or the market. It is a description of how the market currently functions.
